Created at Source Raw Value Validated value
June 27, 2024, 4 p.m. usa

inclusion criteria: * ≥18 years of age at screening. * the subject or a legally authorized representative has provided written informed consent. * hospitalized covid-19 subjects without respiratory failure who are either not receiving any oxygen therapy or are receiving supplemental oxygen via mask or nasal prongs. * male or non-pregnant, non-lactating female subjects with sars-cov-2 infection documented by a hospital approved diagnostic test (eg, a food and drug administration authorized test in the us) within 7 days prior to randomization.

inclusion criteria: * ≥18 years of age at screening. * the subject or a legally authorized representative has provided written informed consent. * hospitalized covid-19 subjects without respiratory failure who are either not receiving any oxygen therapy or are receiving supplemental oxygen via mask or nasal prongs. * male or non-pregnant, non-lactating female subjects with sars-cov-2 infection documented by a hospital approved diagnostic test (eg, a food and drug administration authorized test in the us) within 7 days prior to randomization.

Nov. 18, 2020, 12:31 a.m. usa

inclusion criteria: - ≥18 years of age at screening. - the subject or a legally authorized representative has provided written informed consent. - hospitalized covid-19 subjects without respiratory failure who are either not receiving any oxygen therapy or are receiving supplemental oxygen via mask or nasal prongs. - male or non-pregnant, non-lactating female subjects with sars-cov-2 infection documented by a hospital approved diagnostic test (eg, a food and drug administration authorized test in the us) within 7 days prior to randomization.

inclusion criteria: - ≥18 years of age at screening. - the subject or a legally authorized representative has provided written informed consent. - hospitalized covid-19 subjects without respiratory failure who are either not receiving any oxygen therapy or are receiving supplemental oxygen via mask or nasal prongs. - male or non-pregnant, non-lactating female subjects with sars-cov-2 infection documented by a hospital approved diagnostic test (eg, a food and drug administration authorized test in the us) within 7 days prior to randomization.